



GCRI Annual Report 2021-2022

Q3. ONGOING EXTRAMURAL RESEARCH PROJECTS APRIL 2021 - MARCH 2022

No.	Name of PI	Project Title	Funded by
Cytogenetics Lab			
1	Dr Pina Trivedi	Assessment of MYC and BCL2 and/or BCL6 rearrangements in high-grade B-cell lymphoma	GCS/GCRI
2	Dr Pina Trivedi	Identification of oligodendroglia specific chromosomal changes 1p36/19q13.3 co-deletion by FISH analysis	GCS/GCRI
3	Dr Dharmesh Patel	Clinical significance of molecular cytogenetic studies in acute lymphoblastic leukemia patients	GCS/GCRI
4	Dr Dharmesh Patel	Cytogenetic exploration of Ewing sarcoma with emphasis on rearrangement of EWSR1 gene	GCS/GCRI
Collaborative Projects-Immuno-hematology and Oncopathology Labs			
5	Dr Priti Trivedi Dr Hemangini Vora	Study of hormonal markers and proliferative markers in pituitary adenoma-Completed	GCS/GCRI
6	Dr Priti Trivedi Dr Kruti Rajvik	Histological and molecular subtyping of medulloblastoma using immunohistochemical markers and its prognostic significance	GCS/GCRI
7	Dr Jahnvi Gandhi Dr Kruti Rajvik	Detection of ALK1, ROS-1, PDL1 using immunohistochemistry in non-small cell carcinoma of lung	GCS/GCRI
Immunohaematology Lab			
8	Dr Hemangini Vora	Development of miRNA profiling based signature of potential clinical relevance in triple negative breast cancer	GSBTM
9	Dr Kruti Rajvik Dr Hemangini Vora	Evaluation of HKII and LDH isoenzymes LDHA and LDHB in lung cancer patients	GCS/GCRI
10	Dr Nupur Patel Dr Hemangini Vora	Role of notch receptors in triple negative breast cancer	GCS/GCRI
11	Dr Hemangini Vora Dr Prabhudas Patel Dr Nandita Ghosh Dr Pina Trivedi	Development and validation of biomarkers and drug targets by molecular profiling of triple negative breast cancer-Completed	GSBTM
Medical Oncology			
12	Dr Harsha Panchal	I3Y-CR-JPBQ: A Randomized, double-blind, placebo-controlled, phase III study to compare NSAI (Anastrozole or Letrozole) plus Abemaciclib, a CDK4 and CDK6 inhibitor, or plus placebo, and to compare Fulvestrant plus Abemaciclib or plus placebo in postmenopausal women with hormone receptor-positive, HER2-negative locoregionally recurrent or metastatic breast cancer	Eli Lilly/IQVIA



GCRI Annual Report 2021-2022

No.	Name of PI	Project Title	Funded by
13	Dr Harsha Panchal	RI-02-003: Reditux™ Registry to compare effectiveness, safety, and resource utilization of Reditux™ vs. the reference medicinal product to treat diffuse large B-cell lymphoma and chronic lymphocytic leukaemia in routine clinical practice	Dr Reddy's Laboratory
14	Dr Harsha Panchal	0329-17: A single arm, multicentric, open label, efficacy and safety study of Docetaxel lipid suspension for injection of Intas Pharmaceuticals Limited, India in patients with metastatic castration resistant prostate cancer	Intas (Lambda)
15	Dr Harsha Panchal	0063-17: A global, multicenter, three arms, open-label randomized study to evaluate the efficacy and safety of Nanosomal Docetaxel Lipid Suspension compared to Taxotere® (Docetaxel Injection Concentrate) in triple-negative breast cancer patients with locally advanced or metastatic breast cancer after failure to prior chemotherapy	Intas (Lambda)
16	Dr Harsha Panchal	D9102C00001 - A phase II randomized, multi-center, double-blind, global study to determine the efficacy and safety of Durvalumab plus Olaparib combination therapy compared with durvalumab monotherapy as maintenance therapy in patients whose disease has not progressed following standard of care platinum-based chemotherapy with durvalumab in first-line stage IV non-small cell lung cancer (ORION)	Astrazeneca/ Covance
17	Dr Harsha Panchal	A single arm study to evaluate the safety of Dacomitinib for the first-line treatment of participants in india with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR)-activating mutations	Pfizer/ICON
18	Dr Harsha Panchal	Single arm study to evaluate the safety of Dacomitinib for the first-line treatment of participants in india with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR)-activating mutations	Pfizer/ICON
19	Dr Harsha Panchal	A randomized, double-blind, placebo-controlled phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC).	BAYER/Covance
20	Dr Harsha Panchal	A phase III, randomized, open-label, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of adjuvant endocrine monotherapy in patients with estrogen receptor-positive, HER2-negative early breast cancer	Roche/PPD
21	Dr Shashank Pandya	A phase III randomized controlled study of inj. Proluton (Hydroxyprogesterone caproate) as single dose preoperative therapy in patients with high risk operable breast cancer	Tata Memorial Center



GCRI Annual Report 2021-2022

No.	Name of PI	Project Title	Funded by
22	Dr Shashank Pandya	Randomized controlled trial to assess blockade of voltage gated sodium channels during surgery in operable breast cancer	Tata Memorial Center
23	Dr Priti Sanghavi	A multi-centre, randomized, double blind, parallel-group, comparative clinical trial to evaluate the safety and clinical equivalence of Generic Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) to Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) in subjects with oropharyngeal candidiasis	ThinQ Pharma
24	Dr Kajal Shah	A randomised, double-blind, parallel-group, phase III study to compare the efficacy, safety, and immunogenicity of proposed Rituximab Biosimilar (DRL_RI) with MabThera® in subjects with previously untreated, stage ii-iv, cluster of differentiation (CD)20-positive, low tumour burden follicular lymphoma	Parexel (Dr. Reddy's)
Molecular Diagnostics and Research Laboratory I			
25	Dr Nandita Ghosh Dr Pariseema Dave	To explore the clinical value of molecular markers in epithelial ovarian cancer-A preliminary study	GCS/GCRI
26	Dr Nandita Ghosh	Clinical significance of expression of inflammatory response genes and DNA repair genes in colorectal carcinoma	GCS/GCRI
27	Dr Toral Mandalia	Exploring the role of miR-200 family in ovarian cancer patients	GCRI
28	Dr Toral Mandalia	Significance of molecules associated with cancer stemness in epithelial ovarian cancer	GCRI
Molecular Diagnostics and Research Laboratory II			
29	Dr Trupti Trivedi	Exploring significance of STAT3 signalling pathway in IDH wild type glioma patients	GCRI/GCS
30	Dr Trupti Trivedi	Elucidating clinical impact of Notch signalling pathway for medulloblastoma patients	GCRI/GCS
Molecular Diagnostic and Research Laboratory III			
31	Dr Jayendrakumar Patel	Evaluation of association of p16 expression with presence of HPV DNA in oropharyngeal cancer patients	GCRI/GCS
32	Dr Jayendrakumar Patel	Clinical Significance of JAK2V617F mutation and its validation droplet digital PCR method for myeloproliferative diseases	GCS-GCRI
33	Dr Prabhudas Patel	Significance of Galactin-3 in association with glycosylation in oral cancer	ICMR
34	Dr Hemangini Vora Dr Prabhudas Patel Dr Trupti Trivedi Dr Jayendrakumar Patel	Development and validation of biomarker Panel for early detection and enhanced management of oral (Buccal Mucosa) cancer-Completed	GSBTM



GCRI Annual Report 2021-2022

No.	Name of PI	Project Title	Funded by
Molecular Diagnostic and Research Laboratory IV			
35	Dr Franky Shah	Evaluation of YAP/TEZ axis in breast cancer	GCS/GCRI
Oncopathology			
36	Dr Amisha Gami	Cytogenetic exploration of Ewing sarcoma with emphasis on rearrangement of EWSRI gene	GCRI
37	Dr Beena Brahmbhatt	Assessment of MYC and BC12 and /or BC16 rearrangements in high-grade B cell lymphoma	GCRI
38	Dr Priti Trivedi	Histological and molecular subtyping of medulloblastoma using immunohistochemical markers and its prognostic significance	GCRI

